Multivalent bi-specific nanobioconjugate engager for targeted cancer immunotherapy.


Tumour-targeted immunotherapy offers the unique advantage of specific tumouricidal effects with reduced immune-associated toxicity. However, existing platforms suffer from low potency, inability to generate long-term immune memory and decreased activities against tumour-cell subpopulations with low targeting receptor levels. Here we adopted a modular design… (More)
DOI: 10.1038/nnano.2017.69

4 Figures and Tables


  • Blog articles referencing this paper

  • Presentations referencing similar topics